This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Joint Corp. (JYNT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 433.33% and 5.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate The Joint Corp. (JYNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Joint Corp. (JYNT) Q4 Earnings Lag Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -20.00% and 2.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Centene's (CNC) Hawaii Arm to Keep Offering Healthcare Services
by Zacks Equity Research
Centene's (CNC) Hawaii subsidiary 'Ohana Health Plan is selected to continue catering services via the CSS plan.
Humana (HUM) Joins IBM Watson Health to Aid Member Experience
by Zacks Equity Research
Humana (HUM) teams up with IBM Watson Health to leverage the latter's conversational AI solution for providing better information to Humana Employer Group members.
3 Health Insurers That Crushed S&P YTD, Set to Rise Further
by Srijita Guha
We zero in on three health insurers that outperform the S&P Index YTD on the back of solid fundamentals. All these stocks hold prospects to continue the rally going forward.
Humana (HUM) Offers Medicare Advantage Health Plans for 2021
by Zacks Equity Research
Humana (HUM) unveils 2021 Medicare product offerings and better benefits in more counties across the nation.
Select Medical Enters Into Joint Venture With Rush University
by Zacks Equity Research
Select Medical (SEM) forms a joint venture with Rush University to manage healthcare operations at facilities in Chicago and Northwest Indiana area.
Humana's New Value-Based Care Plans to Better Healthcare
by Zacks Equity Research
Humana's (HUM) enriched value-based care programs are expected to curtail expenses as well as boost quality of healthcare.
Humana (HUM) Taps Salesforce for Better Healthcare Services
by Zacks Equity Research
Humana (HUM) teams up with Salesforce to provide improved healthcare services for its members.
Top Ranked Momentum Stocks to Buy for September 1st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 1st.
Joint Corp's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in The Joint Corp.
Top Ranked Momentum Stocks to Buy for August 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th.
Zacks Industry Outlook Highlights: SEM, MOH, JYNT and HUM
by Zacks Equity Research
Zacks Industry Outlook Highlights: SEM, MOH, JYNT and HUM
Solid Near-Term HMO Industry Prospects on Multiple Tailwinds
by Sapna Bagaria
Health insurers are on a solid ground, given rising demand for Medicare policies, led by the increasing baby boomer population.
Here's Why You Should Add Humana (HUM) to Your Portfolio
by Zacks Equity Research
Riding high on its Medicare line of business and strategic initiatives, Humana (HUM) holds enough potential to reap benefits for investors.
Earnings Preview: The Joint Corp. (JYNT) Q2 Earnings Expected to Decline
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE
by Debanjana Dey
Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Riding high on its robust Medicare business line and strategic initiatives, Humana (HUM) holds potential to reap benefits for investors.
Why Should You Hold on to Centene Stock in Your Portfolio?
by Zacks Equity Research
Riding high on a healthy revenue stream and a solid 2020 guidance, Centene (CNC) holds potential to benefit its investors.
Anthem (ANTM) Issues Policies for Safe Coronavirus Testing
by Zacks Equity Research
Anthem (ANTM) issues updates to ease care provider protocols regarding COVID-19 testing
The Joint Corp. (JYNT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 12.50% and 4.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Reduces 2020 Earnings Estimates, Shares Slide
by Zacks Equity Research
Centene (CNC) updates its 2020 outlook that reflects its WellCare buyout and the potential Medicaid rate decrease.
Anthem's (ANTM) Beacon Health Buyout to Bolster Portfolio
by Zacks Equity Research
Anthem (ANTM) carries on with its acquisition spree, the latest being the purchase of Beacon Health.
The Joint Corp. (JYNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.